AmericanPeptide
Catalog/CJC-1295 (no DAC) + Ipamorelin

CJC-1295 (no DAC) + Ipamorelin

Also known as CJC-1295/Ipamorelin · Mod GRF 1-29 + Ipamorelin · CJC Ipa

The classic growth-hormone pairing — a GHRH analog (CJC-1295 no-DAC / Mod GRF 1-29) plus a selective secretagogue (Ipamorelin) that act on two different receptors.

Research refreshed

Overview

A combination of CJC-1295 without DAC (the short-acting GHRH analog also called Mod GRF 1-29) and Ipamorelin, a selective ghrelin-receptor secretagogue. The two are paired because they raise growth hormone through different receptors: CJC-1295 supplies a GHRH signal to the somatotroph, while Ipamorelin acts on the GHS-R to amplify the pulse without the cortisol or prolactin rise of older GHRPs. It is one of the most common GH-secretagogue pairings in the research literature, and a research combination rather than an approved product.

Background

The logic of this pair is that the somatotroph can be pushed from two directions at once. CJC-1295 without DAC provides the GHRH input that tells the pituitary to make and release growth hormone; Ipamorelin acts through the separate ghrelin receptor to sharpen the release pulse. Because the two receptors are distinct, a combined signal is studied for a larger, still-pulsatile GH release than either input gives on its own.

Ipamorelin was chosen for these pairings specifically because it is selective — it drives GH without the appetite, cortisol, and prolactin effects seen with earlier secretagogues such as GHRP-6. The combination is widely referenced but remains a research construct: it is not an FDA-approved drug, and the component peptides are studied individually.

Mechanism

CJC-1295 (no DAC): GHRH-receptor agonism driving GH synthesis and release. Ipamorelin: GHS-R1a agonism amplifying the GH pulse with high selectivity (minimal ACTH/cortisol/prolactin). Dual-receptor stimulation is studied for a larger, more physiologic pulse than either alone.

Key research findings

  • Two-receptor design — GHRH (CJC-1295) plus GHS-R (Ipamorelin) stimulation is studied for a larger GH pulse than either pathway alone.
  • Selective secretagogue — Ipamorelin amplifies GH with minimal cortisol/prolactin, the reason it is favored over GHRP-6 in these blends.
  • Preserved pulsatility — the no-DAC CJC-1295 is short-acting, keeping GH release pulsatile rather than continuously elevated.
  • Not FDA-approved — a research combination, not an approved therapeutic.

How CJC-1295 (no DAC) + Ipamorelin is made

Behind every vial of CJC-1295 (no DAC) + Ipamorelin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how CJC-1295 (no DAC) + Ipamorelin, specifically, is brought into being.

  1. On paper first

    CJC-1295 (no DAC) + Ipamorelin begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.

  2. Built residue by residue

    CJC-1295 (no DAC) + Ipamorelin is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.

  3. Purity is won here

    The crude mixture — CJC-1295 (no DAC) + Ipamorelin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.

  4. Proven, then protected

    A real batch of CJC-1295 (no DAC) + Ipamorelin proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of CJC-1295 (no DAC) + Ipamorelin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.

Walk the full synthesis pipeline

Handling, storage & why purity is hard

A physical mixture, not a single molecule. CJC-1295 (no DAC) and Ipamorelin are synthesized and purified separately, so there is no combined synthesis and no single purity number — a real certificate gives each peptide its own identity and purity assay and states how much of each is present. Co-dissolving two peptides also adds stability questions a single-peptide vial does not have.

Storage
Store lyophilized, frozen, and protected from light; after reconstitution keep refrigerated and use within a short window. The blend is only as stable as its least stable component.
Handling
Reconstitute gently and treat the certificate as needing per-component data — identity, purity, and content for both the GHRH analog and the secretagogue — rather than one blended figure.

Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.

How peptides are made — the full pipeline

Research areas

  • Growth-hormone secretagogue research
  • GH pulse amplification
  • Body-composition models

Research-area guides

Frequently asked questions

What is CJC-1295 + Ipamorelin?+

A pairing of a GHRH analog (CJC-1295 without DAC, aka Mod GRF 1-29) and a selective GH secretagogue (Ipamorelin) that raise growth hormone through two different receptors.

Why combine a GHRH analog with a GHRP?+

They act on separate receptors — GHRH and the ghrelin receptor — so the combined signal is studied for a larger, still-pulsatile GH release than either component alone.

Why Ipamorelin specifically?+

Ipamorelin is the most selective GH secretagogue, raising GH with little effect on cortisol or prolactin, which is why it is paired in these blends rather than GHRP-6.

Is it approved?+

No — it is a research combination and not FDA-approved. This page is a research and educational reference.

Components

CJC-1295 (no DAC) + Ipamorelin is a blend. Each component is a single compound with its own catalog monograph — purity, mechanism, and research are documented per component below.

Related peptides

Peptide Agent

Ask the Agent about CJC-1295 (no DAC) + Ipamorelin

Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.